Abstract
Osteoprotegerin (OPG) is involved in bone homeostasis and tumor cell survival. Circulating OPG levels are also important biomarkers of various clinical traits, such as cancers and atherosclerosis. OPG levels were measured in serum or in plasma. In a meta-analysis of genome-wide association studies in up to 10 336 individuals from European and Asian origin, we discovered that variants >100 kb upstream of the TNFRSF11B gene encoding OPG and another new locus on chromosome 17q11.2 were significantly associated with OPG variation. We also identified a suggestive locus on chromosome 14q21.2 associated with the trait. Moreover, we estimated that over half of the heritability of OPG levels could be explained by all variants examined in our study. Our findings provide further insight into the genetic regulation of circulating OPG levels.
Original language | English |
---|---|
Pages (from-to) | 6684-6693 |
Number of pages | 10 |
Journal | Human Molecular Genetics |
Volume | 23 |
Issue number | 24 |
DOIs | |
State | Published - 15 Dec 2014 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected].
Funding
This work was supported by the Hong Kong Research Grant Council; the Small Project Funding HKU 201309176244 and 201109176063; the Bone Health Fund of HKU Foundation and Matching Grant; the CRCG Grant and the Osteoporosis Research Fund of The University of Hong Kong. The GOOD study was supported by the Swedish Research Council, the Swedish Foundation for Strategic Research, COMBINE, the ALF/LUA research grant from the Sahlgrenska University Hospital, the LundbergFoundation,theTorstenandRagnarSöderberg´sFoun-dation, the Novo Nordisk Foundation, the Gustav V and Queen Victoria Freemason Foundation and the European Commission Grant HEALTH-F2 – 2008-201865-GEFOS. The Framingham Heart Study of the NHLBI, NIH and Boston University School of Medicine were supported by the NHLBI’s Framingham Heart Study (N01-HC-25195) and its contract with Affymetrix, Inc. for genotyping services (N02-HL-6-4278). The WHI work was supported in part by an allocation of computing time from the Ohio Supercomputer Center and the National Institute of General Medical Sciences (U01GM092655) as well as HHSN268201100002C, NO1-6H74316, U54RR0024384 and HHSN268200960002C. The MICROS study was supported by the Ministry of Health and Department for Promotion of Educational Policies, Universities and Research of the Autonomous Province of Bolzano, South Tyrol, the South Tyrolean Sparkasse Foundation, and the European Union Framework Program 6 EUROSPAN Project (contract no. LSHG-CT-2006-018947). In addition, D.P.K. received support from NIH (Grant R01 AR/AG 41398). E.J.B. received support from the FHS grants 1RO1HL64753, R01HL076784, 1 R01AG028321 and 2R01H L092577.
Funders | Funder number |
---|---|
Bone Health Fund of HKU Foundation | |
Department for Promotion of Educational Policies, Universities and Research of the Autonomous Province of Bolzano, South Tyrol | |
Osteoporosis Research Fund of The University of Hong Kong | |
Queen Victoria Freemason Foundation | |
South Tyrolean Sparkasse Foundation | |
National Institutes of Health | N02-HL-6-4278, N01-HC-25195 |
National Heart, Lung, and Blood Institute | R01HL076784 |
National Institute of General Medical Sciences | U54RR0024384, U01GM092655, HHSN268201100002C, HHSN268200960002C, NO1-6H74316 |
Ministry of Health | |
Sixth Framework Programme | R01 AR/AG 41398, LSHG-CT-2006-018947 |
Framingham Heart Study | 1RO1HL64753, R01AG028321, 2R01H L092577 |
Ohio Supercomputer Center | |
European Commission | HEALTH-F2 – 2008-201865-GEFOS |
Stiftelsen för Strategisk Forskning | |
Research Grants Council, University Grants Committee | 201109176063, HKU 201309176244 |
Vetenskapsrådet | |
Sahlgrenska Universitetssjukhuset | |
Novo Nordisk Fonden |